199 related articles for article (PubMed ID: 17822250)
21. Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.
Ganly P; Hanrahan V; Baker B; Romeril K
Am J Hematol; 2007 Jan; 82(1):80-2. PubMed ID: 16924638
[TBL] [Abstract][Full Text] [Related]
22. Concurrent JAK2(V617F) mutation and MTHFR(C677T) homozygosity in an adolescent with polycythemia vera: case report and discussion.
Ehmann MR; Goodenough CJ; Lotterman CD; Warrier RP
Clin Pediatr (Phila); 2013 Jul; 52(7):671-4. PubMed ID: 22626845
[No Abstract] [Full Text] [Related]
23. Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera.
Scott LM; Beer PA; Bench AJ; Erber WN; Green AR
Br J Haematol; 2007 Nov; 139(3):511-2. PubMed ID: 17910642
[No Abstract] [Full Text] [Related]
24. JAK2 V617F mutation testing in polycythemia vera: use and impact in an academic practice.
Means RT
Am J Med Sci; 2008 Oct; 336(4):327-9. PubMed ID: 18854675
[TBL] [Abstract][Full Text] [Related]
25. Polycythemia vera is not initiated by JAK2V617F mutation.
Nussenzveig RH; Swierczek SI; Jelinek J; Gaikwad A; Liu E; Verstovsek S; Prchal JF; Prchal JT
Exp Hematol; 2007 Jan; 35(1):32-8. PubMed ID: 17198871
[TBL] [Abstract][Full Text] [Related]
26. [Analysis of the mechanism of polycythemia vera by studying JAK2 mutant-induced signaling pathway].
Funakoshi-Tago M
Yakugaku Zasshi; 2011; 131(8):1183-7. PubMed ID: 21804321
[TBL] [Abstract][Full Text] [Related]
27. After 10years of JAK2V617F: Disease biology and current management strategies in polycythaemia vera.
Grinfeld J; Godfrey AL
Blood Rev; 2017 May; 31(3):101-118. PubMed ID: 27884555
[TBL] [Abstract][Full Text] [Related]
28. [Polycythemia vera and JAK-2 mutation in childhood: a case report].
Braconnier O; Monpoux F; Affanetti M; Bérard E; Sirvent N
Arch Pediatr; 2007 Oct; 14(10):1202-5. PubMed ID: 17693067
[TBL] [Abstract][Full Text] [Related]
29. No evidence for JAK2(V617F) mutation in monoclonal B cells in 2 patients with polycythaemia vera and concurrent monoclonal B cell disorder.
Stijnis C; Kroes WG; Balkassmi S; Marijt EW; van Rossum AP; Bakker E; Vlasveld LT
Acta Haematol; 2012; 128(3):183-6. PubMed ID: 22890406
[TBL] [Abstract][Full Text] [Related]
30. [Diagnosis and therapy of polycythemia vera in the era of JAK2].
Lengfelder E
Dtsch Med Wochenschr; 2013 Feb; 138(7):331-6. PubMed ID: 23393003
[TBL] [Abstract][Full Text] [Related]
31. Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F.
Boissinot M; Cleyrat C; Vilaine M; Jacques Y; Corre I; Hermouet S
Oncogene; 2011 Feb; 30(8):990-1001. PubMed ID: 21042281
[TBL] [Abstract][Full Text] [Related]
32. Atypical haematological presentation in a case of polycythaemia vera with a new variant mutation detected in exon 12: c.1605G>T (p.Met535Ile).
Pita ASA; Azevedo APDS; Reichert A; Silva CJPD; Henriques V; Mendes DS; Reis AMB; Cerqueira R; Torres F; Viana JF
J Clin Pathol; 2018 Feb; 71(2):180-184. PubMed ID: 29021147
[TBL] [Abstract][Full Text] [Related]
33. Imatinib effect on growth and signal transduction in polycythemia vera.
Gaikwad A; Verstovsek S; Yoon D; Chang KT; Manshouri T; Nussenzveig R; Cortes J; Vainchenker W; Prchal JT
Exp Hematol; 2007 Jun; 35(6):931-8. PubMed ID: 17533047
[TBL] [Abstract][Full Text] [Related]
34. Mutations in exon 12 of JAK2 are mainly found in JAK2 V617F-negative polycythaemia vera patients.
Kouroupi E; Zoi K; Parquet N; Zoi C; Kiladjian JJ; Grigoraki V; Vainchenker W; Lellouche F; Marzac C; Schlageter MH; Dosquet C; Scott LM; Fenaux P; Loukopoulos D; Chomienne C; Cassinat B
Br J Haematol; 2008 Aug; 142(4):676-9. PubMed ID: 18503583
[No Abstract] [Full Text] [Related]
35. A new polycythaemia vera-associated SOCS3 SH2 mutant (SOCS3F136L) cannot regulate erythropoietin responses.
Suessmuth Y; Elliott J; Percy MJ; Inami M; Attal H; Harrison CN; Inokuchi K; McMullin MF; Johnston JA
Br J Haematol; 2009 Nov; 147(4):450-8. PubMed ID: 19735488
[TBL] [Abstract][Full Text] [Related]
36. Apparent 'JAK2-negative' polycythaemia vera due to compound mutations in exon 14.
Tiong IS; Casolari DA; Moore S; Nguyen T; Van Velzen MJM; Zantomio D; Scott HS; D'Andrea RJ; Hahn CN; Ross DM
Br J Haematol; 2017 Jul; 178(2):333-336. PubMed ID: 27136492
[No Abstract] [Full Text] [Related]
37. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.
James C; Ugo V; Le Couédic JP; Staerk J; Delhommeau F; Lacout C; Garçon L; Raslova H; Berger R; Bennaceur-Griscelli A; Villeval JL; Constantinescu SN; Casadevall N; Vainchenker W
Nature; 2005 Apr; 434(7037):1144-8. PubMed ID: 15793561
[TBL] [Abstract][Full Text] [Related]
38. Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients.
Besses C; Alvarez-Larrán A; Martínez-Avilés L; Mojal S; Longarón R; Salar A; Florensa L; Serrano S; Bellosillo B
Br J Haematol; 2011 Feb; 152(4):413-9. PubMed ID: 21219298
[TBL] [Abstract][Full Text] [Related]
39. [Acquired mutation of JAK2 tyrosine kinase and polycythaemia vera].
Pargade V; Darnige L; Gaussem P
Ann Biol Clin (Paris); 2006; 64(1):3-9. PubMed ID: 16420986
[TBL] [Abstract][Full Text] [Related]
40. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
